摘要
TACE是原发性肝癌非手术治疗的首选方法，但肿瘤难根治，不易处理肝外转移灶，且多次治疗加重肝损伤，远期疗效较差。索拉非尼可以控制肿瘤血管生成，抑制肿瘤细胞增殖。本文报道2009年2月河南省肿瘤医院对1例中国肝癌分期Ⅱb期的原发性肝癌初诊患者进行TACE联合索拉非尼和抗病毒治疗，患者肝内病灶无活性，肺内转移灶达部分缓解。随访至2012年5月，患者生存39个月，肝功能正常，HBVDNA转为阴性，无介入并发症，卡氏评分100分。
Transcatheter arterial chemoembolization （TACE） was the preferred method of non-operation treatment for hepatoeellular carcinoma （HCC）. Radical resection of HCC remains difficult, extrahepatie metastasis was not easy to deal with, and repeated treatment aggravated the liver injury, so the long-term efficacy was poor. Sorafenib could control tumor angiogenesis and block the proliferation of tumor cells. A male patient with primary HCC and in the stage Ⅱ b according to the Chinese clinical liver cancer staging system was treated by TACE combined with sorafenib and antiviral treatment in Henan Cancer Hospital. After the treatment, the intrahepatic lesions were inactive, and the pulmonary metastasis was partially relieved. The patient was followed up till May 2012, and the survival time was 39 months. The hepatic function was normal, and the hepatitis B virus （HBV） replication was negative. No intervention treatment- related comnlieations were detected and the KPS score was 100.
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2013年第3期236-237,共2页
Chinese Journal of Digestive Surgery
关键词
肝肿瘤
肝动脉化疗栓塞
索拉非尼
介入放射学
Liver neoplasms
Transcatheter arterialchemoembo｜ization
Sorafenib
Inter-ventional radiology
